Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Ordinary shares, par value NIS 0.10 per share
-
Shares outstanding
-
2.05B
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
1.35M
-
Shares change
-
+116K
-
Total reported value, excl. options
-
$2.46M
-
Value change
-
+$251K
-
Put/Call ratio
-
1.08
-
Number of buys
-
16
-
Number of sells
-
-10
-
Price
-
$1.82
Significant Holders of BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share (BLRX) as of Q3 2023
36 filings reported holding BLRX - BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share as of Q3 2023.
BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share (BLRX) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.35M shares
of 2.05B outstanding shares and own 0.07% of the company stock.
Largest 10 shareholders include SUSQUEHANNA INTERNATIONAL GROUP, LLP (237K shares), SABBY MANAGEMENT, LLC (210K shares), MORGAN STANLEY (176K shares), LPL Financial LLC (114K shares), Atria Wealth Solutions, Inc. (110K shares), CITADEL ADVISORS LLC (59K shares), ENVESTNET ASSET MANAGEMENT INC (58.1K shares), Values First Advisors, Inc. (48.3K shares), Geneos Wealth Management Inc. (40.5K shares), and Rathbones Group PLC (39.8K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.